Comparative Pharmacology
Head-to-head clinical analysis: LOTREL versus TECZEM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOTREL versus TECZEM.
LOTREL vs TECZEM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lotrel is a combination of amlodipine (a calcium channel blocker) and benazepril (an ACE inhibitor). Amlodipine inhibits calcium ion influx across cardiac and vascular smooth muscle cells, causing vasodilation and reduced blood pressure. Benazepril inhibits angiotensin-converting enzyme, reducing angiotensin II formation, leading to vasodilation and decreased aldosterone secretion.
Enalapril inhibits angiotensin-converting enzyme (ACE), reducing angiotensin II formation, leading to vasodilation and decreased aldosterone secretion. Diltiazem inhibits calcium ion influx across cardiac and smooth muscle cells, causing coronary vasodilation and decreased myocardial contractility.
Oral: 1 capsule (amlodipine 2.5 mg/benazepril 10 mg) once daily, titrate to maximum 10 mg/40 mg once daily.
1 to 2 tablets (enalapril 5 mg/diltiazem 180 mg) orally once daily. Maximum: 2 tablets daily.
None Documented
None Documented
Amlodipine: 30-50 hours (terminal); steady state in 7-10 days. Benazeprilat: 10-11 hours (terminal); effective half-life 22-24 hours with once-daily dosing.
Terminal elimination half-life: 3-4 hours for diltiazem; clinical context: requires twice-daily dosing due to short half-life.
Amlodipine: 60% renal, 20-25% fecal. Benazeprilat: 85% renal (as benazeprilat and conjugated metabolites), 15% biliary/fecal.
Renal: 40-50% unchanged; hepatic/biliary/fecal: 50-60% as metabolites.
Category C
Category C
Antihypertensive combination
Antihypertensive combination